Plain-English translation of NCT07403188 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a follow-up study for people who have already received , an experimental treatment made from your own immune cells that have been modified in a laboratory. Researchers want to check on your health over time and understand how long this treatment continues to work in your body. The main goal is to catch any delayed side effects that might appear months or even years after your infusion.
When new treatments — especially ones involving gene-modified cells — are tested, doctors need to watch patients carefully for a long time to make sure there are no unexpected problems down the road. This study helps ensure the safety of this medication for future patients who might receive it.
You likely qualify if…
You likely don't qualify if…
As a participant, you will be monitored over time to watch for any delayed side effects from your previous treatment. The study will track how long the modified immune cells remain active in your body. You should expect periodic check-ins with the research team, which may include blood tests, medical evaluations, or health history updates — but the exact schedule will depend on the specific study protocol.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States
Enrollment target
~70 participants
Started
November 2025
Primary completion
January 2041
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kyverna Therapeutics
Kyverna Therapeutics
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.